INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.

The ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed. The objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center. Ten patients were prospectively treated with plasma from COVID-19 convalescent donors. Over 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO2/FiO2) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9°C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%. Although other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function.

Olivares-Gazca JC ，Priesca-Marín JM ，Ojeda-Laguna M ，Garces-Eisele J ，Soto-Olvera S ，Palacios-Alonso A ，Izquierdo-Vega J ，Chacon-Cano R ，Arizpe-Bravo D ，López-Trujillo MA ，Cantero-Fortiz Y ，Fernandez-Lara D ，Ruiz-Delgado GJ ，Ruiz-Argüelles GJ ... -  《Revista de Investigacion Clinica-Clinical and Translational Investigation》

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.

Shen C ，Wang Z ，Zhao F ，Yang Y ，Li J ，Yuan J ，Wang F ，Li D ，Yang M ，Xing L ，Wei J ，Xiao H ，Yang Y ，Qu J ，Qing L ，Chen L ，Xu Z ，Peng L ，Li Y ，Zheng H ，Chen F ，Huang K ，Jiang Y ，Liu D ，Zhang Z ，Liu Y ，Liu L ... -  《-》

Use of convalescent plasma in COVID-19 patients in China.

Zhu M ，Hu K ，Zhu Z 《-》

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol

Janssen M ，Schäkel U ，Djuka Fokou C ，Krisam J ，Stermann J ，Kriegsmann K ，Haberbosch I ，Novotny JP ，Weber S ，Vehreschild M ，Bornhäuser M ，Bullinger L ，Schmitt M ，Liebregts T ，Dreger P ，Lorenz HM ，Plaszczyca A ，Bartenschlager R ，Müller B ，Kräusslich HG ，Halama N ，Jäger D ，Schlenk RF ，Leo A ，Meuer S ，Weigand MA ，Motsch J ，Merle U ，Denkinger CM ，Müller-Tidow C ... -  《Trials》

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.

Eckhardt CM ，Cummings MJ ，Rajagopalan KN ，Borden S ，Bitan ZC ，Wolf A ，Kantor A ，Briese T ，Meyer BJ ，Jacobson SD ，Scotto D ，Mishra N ，Philip NM ，Stotler BA ，Schwartz J ，Shaz B ，Spitalnik SL ，Eisenberger A ，Hod EA ，Justman J ，Cheung K ，Lipkin WI ，O'Donnell MR ... -  《Trials》